[Click e-Stock] "Remed Set for Second-Half Turnaround... Rapid Growth Expected"

On September 15, KB Securities analyzed that Remed is expected to achieve growth centered on aesthetic devices for skin care following a turnaround in the second half of the year.

Remed was established in 2003 and possesses non-invasive stimulation technology utilizing magnetic fields. It is the first listed medical device company in Korea based on electroceuticals. In the first half of this year, the company recorded sales of 12 billion KRW and operating profit of 400 million KRW. Lim Sangguk, a researcher at KB Securities, explained, "With the turnaround in the second half of this year as a starting point, a significant increase in performance is expected next year."

He stated, "In the short term, Remed is expected to see both top-line growth and improved performance, mainly driven by aesthetic devices for skin care and chronic pain treatment devices," adding, "It is a very attractive company that possesses both distinctiveness and growth potential, as it is preparing a variety of electroceutical-based mid- to long-term growth drivers."

First, he predicted that Reftone, a skin regeneration treatment device using shock waves, will serve as a growth momentum. He assessed, "The market for skin regeneration using shock waves is still in its early stages, so rapid growth is expected in the future. Not only can it be used as a standalone procedure, but it can also be combined with existing lifting procedures such as Ulthera and Inmode, allowing for diversified treatment options and rapid market penetration through customized well-aging."

The expansion of indications for electroceuticals is also an anticipated area. He emphasized, "Electroceuticals using magnetic fields stimulate nerves and tissues in a non-invasive manner, resulting in fewer side effects and greater safety, which makes it possible to expand indications to various diseases. There is excellent growth potential through pipeline expansion into areas such as obesity, Parkinson's disease, dementia, stroke, autism, and anxiety."